Literature DB >> 23894728

Nanotechnology for CNS delivery of bio-therapeutic agents.

Lipa Shah1, Sunita Yadav, Mansoor Amiji.   

Abstract

The current therapeutic strategies are not efficient in treating disorders related to the central nervous system (CNS) and have only shown partial alleviation of symptoms, as opposed to, disease modifying effects. With change in population demographics, the incidence of CNS disorders, especially neurodegenerative diseases, is expected to rise dramatically. Current treatment regimens are associated with severe side-effects, especially given that most of these are chronic therapies and involve elderly population. In this review, we highlight the challenges and opportunities in delivering newer and more effective bio-therapeutic agents for the treatment of CNS disorders. Bio-therapeutics like proteins, peptides, monoclonal antibodies, growth factors, and nucleic acids are thought to have a profound effect on halting the progression of neurodegenerative disorders and also provide a unique function of restoring damaged cells. We provide a review of the nano-sized formulation-based drug delivery systems and alternate modes of delivery, like the intranasal route, to carry bio-therapeutics effectively to the brain.

Entities:  

Keywords:  Central nervous system; bio-therapeutics; blood-brain barrier; drug delivery; intranasal delivery; nano-sized formulations; olfactory receptor neurons; systemic delivery

Year:  2013        PMID: 23894728      PMCID: PMC3719983          DOI: 10.1007/s13346-013-0133-3

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  93 in total

1.  Vector-mediated drug delivery to the brain.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-04-05       Impact factor: 15.470

2.  Molecular Trojan horses for blood-brain barrier drug delivery.

Authors:  William M Pardridge
Journal:  Discov Med       Date:  2006-08       Impact factor: 2.970

Review 3.  Nanoparticles for direct nose-to-brain delivery of drugs.

Authors:  Alpesh Mistry; Snjezana Stolnik; Lisbeth Illum
Journal:  Int J Pharm       Date:  2009-06-23       Impact factor: 5.875

4.  Gene delivery into the central nervous system by nasal instillation in rats.

Authors:  R Draghia; C Caillaud; R Manicom; A Pavirani; A Kahn; L Poenaru
Journal:  Gene Ther       Date:  1995-08       Impact factor: 5.250

Review 5.  Drug delivery strategies for Alzheimer's disease treatment.

Authors:  Antonio Di Stefano; Antonio Iannitelli; Sara Laserra; Piera Sozio
Journal:  Expert Opin Drug Deliv       Date:  2011-03-11       Impact factor: 6.648

6.  Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers.

Authors:  Ho Lun Wong; Reina Bendayan; Andrew Mike Rauth; Xiao Yu Wu
Journal:  J Pharm Sci       Date:  2004-08       Impact factor: 3.534

7.  Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations.

Authors:  Tushar K Vyas; Aliasgar Shahiwala; Mansoor M Amiji
Journal:  Int J Pharm       Date:  2007-06-19       Impact factor: 5.875

8.  Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy.

Authors:  George J Francis; Jose A Martinez; Wei Q Liu; Kevin Xu; Amit Ayer; Jared Fine; Ursula I Tuor; Gordon Glazner; Leah R Hanson; William H Frey; Cory Toth
Journal:  Brain       Date:  2008-11-16       Impact factor: 13.501

Review 9.  Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles.

Authors:  Ho Lun Wong; Reina Bendayan; Andrew M Rauth; Yongqiang Li; Xiao Yu Wu
Journal:  Adv Drug Deliv Rev       Date:  2007-05-01       Impact factor: 15.470

10.  Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.

Authors:  Shyeilla V Dhuria; Leah R Hanson; William H Frey
Journal:  J Pharm Sci       Date:  2009-07       Impact factor: 3.534

View more
  15 in total

Review 1.  Nano-enabled delivery of diverse payloads across complex biological barriers.

Authors:  Kathleen A Ross; Timothy M Brenza; Andrea M Binnebose; Yashdeep Phanse; Anumantha G Kanthasamy; Howard E Gendelman; Aliasger K Salem; Lyric C Bartholomay; Bryan H Bellaire; Balaji Narasimhan
Journal:  J Control Release       Date:  2015-08-24       Impact factor: 9.776

Review 2.  Nanomaterial applications in multiple sclerosis inflamed brain.

Authors:  Clara Ballerini; Giovanni Baldi; Alessandra Aldinucci; Pietro Maggi
Journal:  J Neuroimmune Pharmacol       Date:  2015-01-24       Impact factor: 4.147

Review 3.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

4.  Analgesic efficacy and safety of DALDA peptide analog delivery to the brain using oil-in-water nanoemulsion formulation.

Authors:  Lipa Shah; Praveen Kulkarni; Craig Ferris; Mansoor M Amiji
Journal:  Pharm Res       Date:  2014-05-03       Impact factor: 4.200

Review 5.  Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery.

Authors:  Chaitanya R Joshi; Vinod Labhasetwar; Anuja Ghorpade
Journal:  J Neuroimmune Pharmacol       Date:  2017-02-03       Impact factor: 4.147

Review 6.  Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines.

Authors:  Surya K Mallapragada; Timothy M Brenza; JoEllyn M McMillan; Balaji Narasimhan; Donald S Sakaguchi; Anup D Sharma; Svitlana Zbarska; Howard E Gendelman
Journal:  Nanomedicine       Date:  2015-01-31       Impact factor: 5.307

7.  CNS delivery and pharmacokinetic evaluations of DALDA analgesic peptide analog administered in Nano-sized oil-in-water emulsion formulation.

Authors:  Lipa Shah; Florence Gattacceca; Mansoor M Amiji
Journal:  Pharm Res       Date:  2013-12-03       Impact factor: 4.200

8.  Co-delivery of GOLPH3 siRNA and gefitinib by cationic lipid-PLGA nanoparticles improves EGFR-targeted therapy for glioma.

Authors:  Chengkun Ye; Bomin Pan; Haoyue Xu; Zongren Zhao; Jiawei Shen; Jun Lu; Rutong Yu; Hongmei Liu
Journal:  J Mol Med (Berl)       Date:  2019-11-14       Impact factor: 4.599

9.  Anti-transferrin receptor-modified amphotericin B-loaded PLA-PEG nanoparticles cure Candidal meningitis and reduce drug toxicity.

Authors:  Xiaolong Tang; Yong Liang; Yongqiang Zhu; Chunmei Xie; Aixia Yao; Li Chen; Qinglin Jiang; Tingting Liu; Xiaoyu Wang; Yunyun Qian; Jia Wei; Wenxuan Ni; Jingjing Dai; Zhenyou Jiang; Wei Hou
Journal:  Int J Nanomedicine       Date:  2015-10-05

Review 10.  Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease.

Authors:  Bruno Fonseca-Santos; Maria Palmira Daflon Gremião; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2015-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.